The ‘bible for psychiatry’ is getting a rewrite: your guide to the next DSM Could the next version of the DSM be a ‘living’ document that has more focus on the causes of mental illness?

Potential to move away from rigid categories toward more dimensional and cross‑diagnostic construct and greater emphasis on biological and digital markers (e.g., genetics, brain measures, digital phenotyping) alongside symptom checklists , looks promising

www.nature.com/articles/d41...

These reflect small, lifelong genetic differences in target activity, not evidence that statins or PCSK9 inhibitors cause depression. But they do suggest that on-target lipid modulation may shape psychiatric vulnerability
#PsychiatricGenetics #MentalHealth

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug–target Mendelian randomization study - Yan Wang, Xin Liu, Shuo Huang, 2026 Objectives The pleiotropic effects of lipid-lowering therapies on mental health remain incompletely understood. This study aimed to investigate the causal impac...

drug–target MR study on lipid-lowering pathways & mental health.
Genetically proxied inhibition of:
• HMGCR and PCSK9 → modest ↑ risk of major depressive disorder
• PCSK9 → ↑ bipolar disorder risk
• NPC1L1 → ↓ depression risk

journals.sagepub.com/doi/10.1177/...

A stratified precision medicine trial targeting α2A-adrenergic receptor agonism as a treatment for the cognitive biotype of depression - Nature Mental Health This study demonstrates that guanfacine immediate release enhances cognitive control circuit function and behavioral performance in a neurobiologically defined cognitive biotype of depression, achieving a 76.5% clinical response rate and improving life satisfaction, marking a promising advance in precision medicine.

recent clinical trial by Leanne Williams and colleagues investigated guanfacine, an α2A adrenoreceptor agonist traditionally used for high blood pressure, as a targeted treatment for a neurobiologically defined cognitive biotype of major depressive disorder.
www.nature.com/articles/s44...

Excellent opportunity with an amazing supervisor @uclbrainscience.bsky.social

The Use of Pharmacogenomics in Mental Health Pharmacogenomics (PGx) offers a personalized approach to treating mental health disorders, like depression, by using an individual's genetic profile to guide medication selection and dosage. This appr...

Pharmacogenomic(PGx)testing can guide mental health treatment by predicting which meds work best for each patient. Faster response, fewer side effects. For example, CYP2C19 poor metabolizers may need a 50% sertraline dose. A tool worth considering for #GPs & #psychiatrists.
shorturl.at/X827X

Stark Reality - almost half of those who take #antidepressants have tried at least two drugs without success & about third have tried four drugs without success, findings revealed severe emotional distress and frustration with existing treatments amongst patients .
www.cambridge.org/core/journal...

Thank you so much to our wonderful steering committee members (incl. @jonroiser.bsky.social @alexandrapitman.bsky.social @annaremington.bsky.social) for making this possible.

@anabellepauli.bsky.social @lunahuestegge.bsky.social @shalz15.bsky.social @steveallsopp.bsky.social

And our eternal gratitude to the programme steering committee (incl. @jonroiser.bsky.social @alexandrapitman.bsky.social @annaremington.bsky.social) for guiding us through our PhD journeys!

Comprehensive evaluation and performance analysis of machine learning in heart disease prediction - Scientific Reports Scientific Reports - Comprehensive evaluation and performance analysis of machine learning in heart disease prediction

Heart disease prediction model achieved 95% accuracy using advanced AI techniques like feature selection, data balancing,&deep learning. Potential to adapt this for mental health could be incredible-for early diagnosis, personalized care, biomarkers await!
www.nature.com/articles/s41...